• Age ≥18 years, ≤75 years, gender is not limited;

• Squamous esophageal cancer of thoracic segment confirmed by pathology;

• Locally advanced patients with no distant metastasis by imaging, resectable or potentially resectable after discussion among oncology, esophageal surgery, and imaging, and clinical stage cT2-4aN+ or cT3-4aN0, M0, stage II, III, or IVA (AJCC 8th edition cTNM staging);

• ECOG PS score of 0-1;

• No previous antitumor treatment such as radiotherapy, chemotherapy and immunotherapy;

• Expected survival \> 6 months;

• Adequate baseline organ function: (i) WBC ≥3×10\^9/L, ANC ≥1.5×10\^9/L, PLT ≥100×10\^9/L, Hb ≥9g/dL; (ii) Liver function: TBIL ≤2ULN, AST ≤2.5ULN, ALT ≤2.5ULN; (iii) Renal function: cCr\>40 ml/min, Cr≤1.5 ULN; (iv) Cardiac function: no cardiac disease or coronary artery disease. Cardiac function: no heart disease or coronary heart disease, patients with cardiac function grade 1-2;

• Hypertensive patients applying antihypertensive drugs to control blood pressure within the normal range;

• Diabetic patients with fasting blood glucose controlled at ≤8mmol/L by hypoglycemic drug treatment;

⁃ No other serious diseases (such as autoimmune diseases, immunodeficiency, organ transplantation, or other diseases that require continuous hormone therapy) that conflict with this protocol;

⁃ No history of other malignant tumors;

⁃ The patient agrees to participate in this clinical study and signs the Informed Consent Form.